Cxx1c Inhibitors
Chemical inhibitors of Cxx1c can act through various mechanisms to affect its function. Alsterpaullone, a known inhibitor of cyclin-dependent kinases, can disrupt the cell cycle progression by preventing the phosphorylation events that are necessary for Cxx1c activation or function. Similarly, Leptomycin B targets Exportin 1 (CRM1), potentially restricting the ability of Cxx1c to shuttle between the nucleus and cytoplasm, thereby inhibiting its function in the cytoplasm where it may normally exert its effects. U0126 and PD98059, both MEK inhibitors, can downregulate the ERK pathway, which may be crucial for the activity or stability of Cxx1c. By inhibiting MEK1/2, these compounds can reduce the phosphorylation downstream of the ERK pathway, which might be necessary for the proper functioning of Cxx1c.
In parallel, LY294002 and Wortmannin, both phosphoinositide 3-kinases (PI3K) inhibitors, can obstruct the PI3K/AKT pathway, a signaling cascade that can be essential for the activation or stability of Cxx1c. SB203580, which inhibits p38 MAP kinase, can block a different signaling pathway that Cxx1c may require for its activity. SP600125, an inhibitor of c-Jun N-terminal kinase (JNK), can prevent the JNK signaling that may regulate the activity or stability of Cxx1c. Rapamycin, an mTOR inhibitor, can disrupt downstream pathways that involve Cxx1c, leading to its functional inhibition. Bortezomib and MG132, both proteasome inhibitors, can lead to the accumulation of Cxx1c by preventing its degradation, which may result in a functional change. Lastly, Thapsigargin, by inhibiting the SERCA pump and altering calcium homeostasis, can affect the function of Cxx1c if it is calcium-dependent or modulated by calcium signaling. Each of these inhibitors can affect the function of Cxx1c through distinct biochemical pathways, reflecting the complexity of cellular regulation and the multiple points at which Cxx1c can be modulated.
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Alsterpaullone | 237430-03-4 | sc-202453 sc-202453A | 1 mg 5 mg | $67.00 $306.00 | 2 | |
Alsterpaullone is known to inhibit cyclin-dependent kinases (CDKs) which are vital for cell cycle progression. Inhibition of CDKs could lead to the suppression of Cxx1c by preventing the phosphorylation events required for its activation or function. | ||||||
Leptomycin B | 87081-35-4 | sc-358688 sc-358688A sc-358688B | 50 µg 500 µg 2.5 mg | $105.00 $408.00 $1224.00 | 35 | |
Leptomycin B inhibits the export of proteins from the nucleus by binding to Exportin 1 (CRM1). If Cxx1c functions within the nucleus or requires nuclear-cytoplasmic shuttling for its activity, this inhibition could prevent Cxx1c from carrying out its functions in the cytoplasm. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 is an inhibitor of MEK1/2, enzymes upstream of the ERK pathway, which is involved in a wide range of cellular processes. By inhibiting MEK, U0126 would downregulate the ERK pathway which might be crucial for Cxx1c activity or stability. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is a phosphoinositide 3-kinases (PI3K) inhibitor. If Cxx1c relies on PI3K/AKT pathway signaling for its activation or stability, LY294002 would inhibit this signaling, thus functionally inhibiting Cxx1c. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059 is another MEK inhibitor, similar to U0126. It would inhibit Cxx1c by the same mechanism, suppressing the ERK pathway and potentially affecting Cxx1c activity. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin is also a PI3K inhibitor like LY294002, and it would inhibit Cxx1c by blocking the PI3K/AKT pathway if Cxx1c activity is dependent on this pathway. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 is an inhibitor of p38 MAP kinase. If Cxx1c requires p38 MAP kinase signaling for its activity, SB203580 would functionally inhibit Cxx1c by blocking this signaling pathway. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of c-Jun N-terminal kinase (JNK). If Cxx1c activity or stability is regulated by JNK signaling, inhibition by SP600125 would result in functional inhibition of Cxx1c. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin inhibits mTOR, a central protein in regulating cell growth and metabolism. If Cxx1c is involved in pathways downstream of mTOR, rapamycin would result in the functional inhibition of Cxx1c. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $132.00 $1064.00 | 115 | |
Bortezomib is a proteasome inhibitor. If Cxx1c is regulated by proteasomal degradation, inhibition of the proteasome by Bortezomib could lead to altered function or accumulation of non-functional Cxx1c. | ||||||